Low-dose hormone therapy in postmenopausal women in China

Climacteric

Volumn 13, Issue 6, 2010, Pages 544-552

  Zang, H ^a   Shi, H ^a   Speroff, L ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

CHINA; HORMONE THERAPY; LOW DOSE; POSTMENOPAUSAL WOMEN

Indexed keywords

CALCIUM CARBONATE; CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; ESTRIOL; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NYLESTRIOL; PLACEBO; PROGESTERONE; TIBOLONE; UNCLASSIFIED DRUG;

BONE DENSITY; BONE TURNOVER; BREAST TENDERNESS; CARDIOVASCULAR SYSTEM; CHINA; CLIMACTERIUM; CLINICAL ASSESSMENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM; ESTROGEN THERAPY; FEMALE; HORMONAL THERAPY; HUMAN; MASTALGIA; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; VAGINA BLEEDING;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; BONE DENSITY; CARDIOVASCULAR DISEASES; CHINA; ENDOMETRIAL HYPERPLASIA; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; PROGESTERONE; QUINESTROL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78649264925     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130903395201     Document Type: Review

References (62)

1. Speroff L, Fritz MA. Postmenopausal hormone therapy. In Clinical Gynecologic Endocrinology and Infertility, 7th edn. Philadephia: Lippincott Williams & Wilkins, 2005:689-778
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
3. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
4. Pines A, Sturdee DW, Birkhauser MH, et al. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-94
5. Peeyananjarassri K, Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 2005;8:13-23
6. Panay N, Ylikorkala O, Archer DF, et al. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120-31
7. Lundstrom E, Bygdeson M, Svane G, et al. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric 2007;10:249-56
8. Speroff L, Fritz MA. Menopause and the perimenopausal transition. In Clinical Gynecologic Endocrinology and Infertility, 7th edn. Philadephia: Lippincott Williams & Wilkins, 2005:621-88
9. Obermeyer CM. Menopause across cultures: a review of the evidence. Menopause 2000;7:184-92
10. Hilditch JR, Chen S, Norton PG, et al. Experience of menopausal symptoms by Chinese and Canadian women. Climacteric 1999;2:164-73
11. Haines CJ, Xing SM, Park KH, et al. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Maturitas 2005;52:264-76
12. Chen Y, Lin SQ, Wei Y, et al. Impact of menopause on quality of life in community-based women in China. Menopause 2008;15:144-9
13. Tian FL, Yang DZ, Zhang XZ, et al. [Survey of health status and healthcare service demand of perimenopausal women in Guangdong]. Di Yi Jun. Yi Da Xue Xue Bao 2004;24:928-32
14. Lam PM, Leung TN, Haines C, et al. Climacteric symptoms and knowledge about hormone replacement therapy among Hong Kong Chinese women aged 40-60 years. Maturitas 2003;45:99-107
15. Zhang SW, Wang JH, Zhou H, et al. [The investigation and analysis of the factors related with the menopausal age of women in Beijing area]. Beijing Med J 2002;24:177-80
16. Deng XH, Zhang SW. [The epidemiological survey of perimenopausal women in Beijing]. Beijing Med J 2002;24:235-8
17. Chen Y, Lin SQ, Wei Y, et al. Menopause-specific quality of life satisfaction in community-dwelling menopausal women in China. Gynecol Endocrinol 2007;23:166-72
18. Yang D, Haines CJ, Pan P, et al. Menopausal symptoms in mid-life women in southern China. Climacteric 2008;11:329-36
19. MacLennan AH, Taylor AW, Wilson DH. Hormone therapy use after the Women's Health Initiative. Climacteric 2004;7:138-42
20. Xia JH, Tian FL, Zhao QG, et al. [Investigation on women's menopause treatment and attitude toward hormone replacement therapy]. China Public Health 2005;21:83-4
21. Ye BL, Lin QY. [Survey of status of postmenopausal women in Wenzhou District]. Zhonghua Fu Chan Ke Za Zhi 1997;32:557-8
22. Zhang SC, Wei XL, Geng LP, et al. [Progress of healthcare service in perimenopausal women]. Nursing J Chinese People's Liberation Army 2004;21:44-5
23. [National Symposium on Issues of Perimenopausal and Postmenopausal Women - Summary]. Zhonghua Fu Chan Ke Za Zhi 1997;32:520-3
24. Zhou YZ, Lin SQ, Jiang YX, et al. [Effects of continuous combined estrogen and progesterone for a year on breast in postmenopausal women]. Zhonghua Fu Cha Ke Za Zhi 2003;38:34-5
25. Ge Q, Tian Q, Tseng H, et al. Development of lowdose reproductive hormone therapies in China. Gynecol Endocrinol 2006;22:636-45
26. OCPS research group in Shanghai. [Clinical and laboratory research on reduced doses of oral contraceptives]. Family Plann Drugs (Chin) 1978;1:S77-98
27. Du Z, Sun M, Wang B, et al. [The effects of sex hormone on blood vessels]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1999;21:282-7
28. Nie M, Sun ML, Ge QS. [Effects of long-term and lowdose hormone replacement therapy on bone mineral density in postmenopausal women]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2006;28:421-4
29. Hu L, Yue Y, Zuo PP, et al. Evaluation of neuroprotective effects of long-term low dose hormone replacement therapy on postmenopausal women brain hippocampus using magnetic resonance scanner. Chin Med Sci J 2006;21:214-18
30. Luan Q, Luan MY, Li GZ. [Prospective study of low dose hormonal replacement therapy on the treatment of climacteric symptoms in postmenopausal women].]. J Weifang Med Coll 1998;20:81-2
31. Xing S, Wu Y, Liu J, et al. A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin. Chin Med J (Engl) 2003;116:584-7
32. Tan D, Haines CJ, Limpaphayom KK, et al. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. Maturitas 2005;52:35-51
33. Zhang ZL, Dong ZN, Liu H, et al. [Effects of continuous combined Dermstril and medroxyprogesterone acetate replacement therapy on climacteric symptoms and lumbar vertebral bone loss].]. J Reprod Med 2002;11:274-8
34. Bai WP, Chen SL, Zheng SY, et al. [The treatment effect of transdermal estrogen patches on menopausal syndrome and its effect on serum lipoprotein metabolism].]. Maternal Child Health Care China 2005;20:499-501
35. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21-8
36. Cheng J, Ye BL, Li CY. [Effects of low dose hormone replacement therapy on cardiovascular system in postmenopausal women]. J Chinese Ageing 2005;25:1308-10
37. Song YX, Guan Y, Liu Y. [Therapeutic study of low dose hormone treatment in postmenopausal women]. J Med Forum 2008;29:71-2
38. Wu FL, Wu YY, Shi HY. [Effects of different types of low dose sex hormone on quality of life in postmenopausal women]. Chin J Med 2006;41:36-7
39. Haines CJ, Yim SF, Chung TK, et al. A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women. Maturitas 2003;44:207-14
40. Lu J, Lin S, Zhang L, et al. [Prevention of bone loss by estradiol valerate combined with medroxyprogesterone acetate among postmenopausal women with osteopenia].]. Zhonghua Yi Xue Za Zhi 2002;82:1593-8
41. Weng SQ. [Low dose of estrogen on treatment of postmenopausal osteoporosis]. Reprod Contracept 2007;27:794-7
42. Sun A, Lin S, Wei Y. [Observation of preventing of bone loss during early postmenopause by percutaneous estradiol in Chinese postmenopausal women].]. Zhonghua Fu Chan Ke Za Zhi 2001;36:348-51
43. Li LZ, Gao ZQ, Zhang PS, et al. [Effects of low dose hormonal replacement therapy on bone metabolism in postmenopausal women]. J Clin Orthopaedics 1998;1:30-1
44. Wu YY, Liu JL, Xing SM, et al. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].]. Zhonghua Fu Chan Ke Za Zhi 2002;37:762-5
45. Shang M, Yang X, Luan YQ, et al. [Effects of small dose estrogen and progesterone on prevention and treatment of perimenopausal osteoporosis]. Chin J Osteoporos 2005;11:424-6
46. Li WQ, Zhou ZL, Li X, et al. [Study on the therapeutic effect of small dose of estradiol and progestrone on post-menopauseal osteoporosis]. J Radioimmunol 2004;17:1-3
47. Gambacciani M, Cappagli B, Ciaponi M, et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008;59:2-6
48. Ausmanas MK, Holinka CF, Ling YS, et al. Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study. Climacteric 2007;10:306-13
49. He FF, Sun AJ, Qin MW, et al. [The effect of low dose Livial in prevention and management of postmenopausal women]. J Reprod Med 2000;9:71-6
50. Luan Q, Li LZ, Luan MY, et al. [Effects of low dose of hormone replacement therapy on lipids in postmenopausal women]. Zhonghua Fu Chan Ke Za Zhi 2000;35:181-2
51. Luan MY, Luan Q, Li LZ. [Effects of low dose hormonal replacement therapy on glucose metabolism in postmenopausal women]. J WeiFang Med Coll 1998;20:87-8
52. Shi YF, Yang WW. [The effect of lower doses hormone replacement therapy on homocysteine serum level in postmenopausal women]. J Bethune Military Med Coll 2005;3:77-9
53. Sadoon S, Salman G, Smith G, et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in postmenopausal bleeding. J Obstet Gynaecol 2007;27:406-8
54. Chen R, Lin S, Yang X, et al. [A randomized, mutlticenter, double blind and parallel controlled clinical trial for Kuntai capsules in the treatment of climacteric syndromes].]. Chin J New Drugs 2005;14:1472-6
55. Gong LL, Zhang SF, Ji L, et al. [Effect of low-dose hormone therapy on breast at the early stage of menopause]. J Pract Obstet Gynecol 2009;25:104-7
56. Wang SH, Lin SQ, Gui QF, et al. [Profiles of irregular bleeding induced by low-dose hormone therapy and Chinese formulated herbs products]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2006;28:256-61
57. Wang ZQ, Liu J. [Recent progress of nylestriol in preventing postmenopausal osteoporosis and lipoprotein lipids disorders]. Chin J New Drugs 1996;5:335-8
58. Liu JL. [Effect of nylestriol on postmenopausal uterine endometrium]. Zhonghua Fu Chan Ke Za Zhi 1993;28:76-8, 122
59. Cheng GJ, Liu JL, Zhang Q, et al. Nylestriol replacement therapy in postmenopausal women. A three-year prospective study. Chin Med J (Engl) 1993;106:911-16
60. Zhang JF, Yang JL, Zhou MZ, et al. [Lipids regulating effects of small dose nylestriol on lipoprotein (a) and lipids in postmenopausal woman]. Clin Cardiol (China) 1999;15:122-4
61. Liao EY, Luo XH, Deng XG, et al. The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis. Endocr Res 2003;29:217-26
62. Cheng GJ. [Prospective study on nylestriol replacement therapy in postmenopausal women]. Zhonghua Fu Chan Ke Za Zhi 1993;28:534-8